Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NIH × Melanoma × ixabepilone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 5 Breast Neoplasms 5 Sarcoma 3 Carcinoma, Renal Cell 3 Wilms Tumor 2 Unspecified Adult Solid Tumor, Protocol Specific 2 Testicular Neoplasms 2 Teratoma 2 Squamous Cell Carcinoma of Head and Neck 2 Salivary Gland Neoplasms 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Ovarian Neoplasms 2 Osteosarcoma 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Neuroblastoma 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Mantle-Cell 2 Lymphoma, Large-Cell, Anaplastic 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, Follicular 2 Kidney Neoplasms 2 Central Nervous System Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Burkitt Lymphoma 2 Breast Neoplasms, Male 2 Astrocytoma 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Tongue Neoplasms 1

Interventions

aldesleukin 61 Cyclophosphamide 43 fludarabine phosphate 28 fludarabine 27 Interleukin-2 22 incomplete Freund's adjuvant 21 Ipilimumab 15 Specimen Handling 13 Magnetic Resonance Spectroscopy 12 MART-1 Antigen 12 CTLA-4 Antigen 12 sargramostim 11 montanide ISA 51 11 Biopsy 11 Sorafenib 10 Filgrastim 10 Nivolumab 9 pembrolizumab 8 Interferon-alpha 8 trametinib 7 dabrafenib 7 Sirolimus 7 Bevacizumab 7 temsirolimus 6 Temozolomide 5 Introns 5 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5 cediranib 4 cabozantinib 4 Whole-Body Irradiation 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00036764 2013-01-25

BMS-247550 in Treating Patients With Stage IV Melanoma

National Cancer Institute (NCI)

Phase 2 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡